Clinical Trial Update: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for an anti-CD38 antibody drug conjugate in relapsed or refractory multiple myeloma spanning Phase 1 and Phase 2, currently ACTIVE_NOT_R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-CD38 antibody-drug conjugate

Snippet

Sponsor: Sorrento Therapeutics, Inc. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING